Virpax Pharmaceuticals, Inc. announced on July 24, 2024, that it has regained compliance with the Nasdaq minimum bid price requirement. The company's common stock had maintained a closing bid price of $1.00 or greater for 10 consecutive business days, from July 8 to July 19, 2024. This achievement has led to the closure of the listing matter, as confirmed by the Nasdaq Listing Qualifications Department. Virpax specializes in developing non-addictive products for pain management, PTSD, CNS disorders, and anti-viral indications. The company is working on FDA approval for two prescription drug candidates and has cooperative research and development agreements with the NIH and DOD. Additionally, Virpax is pursuing approval for two nonprescription products, including one for inhibiting viral replication in influenza or SARS-CoV-2.

Virpax Pharmaceuticals, Inc. announced on July 24, 2024, that it has regained compliance with the Nasdaq minimum bid price requirement. The company's common stock had maintained a closing bid price of $1.00 or greater for 10 consecutive business days, from July 8 to July 19, 2024. This achievement has led to the closure of the listing matter, as confirmed by the Nasdaq Listing Qualifications Department. Virpax specializes in developing non-addictive products for pain management, PTSD, CNS disorders, and anti-viral indications. The company is working on FDA approval for two prescription drug candidates and has cooperative research and development agreements with the NIH and DOD. Additionally, Virpax is pursuing approval for two nonprescription products, including one for inhibiting viral replication in influenza or SARS-CoV-2.